search
Back to results

The Effect of Vitamin D3 Therapy on Vitamin D Status in Pregnant Women With Vitamin D Deficient and Insufficient

Primary Purpose

Vitamin D Deficiency

Status
Active
Phase
Phase 2
Locations
Indonesia
Study Type
Interventional
Intervention
Cholecalciferol
Sponsored by
Indonesia University
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Vitamin D Deficiency

Eligibility Criteria

undefined - undefined (Child, Adult, Older Adult)FemaleAccepts Healthy Volunteers

Inclusion Criteria: pregnant women with gestational age of ≤ 14 weeks vitamin D deficient or insufficient (25(OH)D <30 ng/ml] positive fetal heart rate from ultrasound examination. Exclusion Criteria: multiple pregnancy pregnancy with congenital anomaly hyperemesis gravidarum, diarrhea complicated medical history (hypertension, diabetes mellitus, heart, kidney, or liver disease) use of any dietary supplement containing vitamin D prior to enrolment

Sites / Locations

  • Cipto Mangunkusumo National Center General Hospital

Arms of the Study

Arm 1

Arm 2

Arm Type

Experimental

Active Comparator

Arm Label

50,000 IU

5,000 IU

Arm Description

Vitamin D3 50,000 IU weekly a standard prenatal multivitamin (fumarate Fe 90 mg; folic acid 0.4 mg; vitamin B6 3 mg; vitamin B12 5 mcg; sulphate cupric 0.35 mg, sulphate cobalt 0.15 mg, sulphate mangan 5 mcg, vitamin C 60 mg, vitamin E 5 mg, and phosphate calcium 60 mg)

Vitamin D3 5,000 IU daily a standard prenatal multivitamin (fumarate Fe 90 mg; folic acid 0.4 mg; vitamin B6 3 mg; vitamin B12 5 mcg; sulphate cupric 0.35 mg, sulphate cobalt 0.15 mg, sulphate mangan 5 mcg, vitamin C 60 mg, vitamin E 5 mg, and phosphate calcium 60 mg)

Outcomes

Primary Outcome Measures

25(OH)D maternal serum level
quantified by direct competitive Chemilumiscence Immunoassay (CLIA) using LIAISON®.
1,25(OH)2D maternal serum level
quantified by Liquid Chromatography-tandem Mass Spectrometry (LC-MS/MS) using ImmuTube®.
VDBP maternal serum level
quantified by Enzyme-Linked Immunosorbent Assay (ELISA) using Quantikine®
24,25(OH)2D maternal serum level
quantified by Acquity I Class Binary Solvent Manager FTN , Xevo TQXS Tandem Mass Spectrometry (Waters Corporation)

Secondary Outcome Measures

Full Information

First Posted
September 5, 2023
Last Updated
September 22, 2023
Sponsor
Indonesia University
search

1. Study Identification

Unique Protocol Identification Number
NCT06054919
Brief Title
The Effect of Vitamin D3 Therapy on Vitamin D Status in Pregnant Women With Vitamin D Deficient and Insufficient
Official Title
The Effect of Vitamin D3 Therapy on 25(OH)D, 1,25(OH)2D, VDBP, and 24,25(OH)2D Maternal Serum Levels in Pregnant Women With Vitamin D Deficient and Insufficient
Study Type
Interventional

2. Study Status

Record Verification Date
September 2023
Overall Recruitment Status
Active, not recruiting
Study Start Date
April 1, 2021 (Actual)
Primary Completion Date
November 30, 2023 (Anticipated)
Study Completion Date
November 30, 2023 (Anticipated)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
Indonesia University

4. Oversight

Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
Yes

5. Study Description

Brief Summary
This study is a randomized controlled trial which compares the effect of vitamin D3 therapy 5,000 IU daily and 50,000 IU on 25(OH)D and 1,25(OH)2D, VDBP, and 24,25(OH)2D maternal serum levels in pregnant women with vitamin D deficient and insufficient.
Detailed Description
This is a randomized controlled trial of vitamin D therapy of 5,000 IU daily or 50,000 IU weekly during pregnancy. The study is conducted at Cipto Mangunkusumo National Center General Hospital and Koja Distict Hospital in Jakarta, Indonesia from April 2021 - December 2023. All the pregnant women are screened for eligibility when they presented to the clinic for antenatal care visits and are offered enrolment if they meet the following inclusion criteria: gestational age of ≤ 14 weeks, vitamin D deficient or insufficient (25(OH)D <30 ng/ml], and positive fetal heart rate from ultrasound examination. Participants are randomly assigned to one of two parallel intervention groups, with allocation concealment: vitamin D3 (cholecalciferol) 5,000 IU/week or 50,000 IU/week. All participants are given a standard prenatal multivitamin. A medical history, physical, and ultrasound examination are performed. Participants complete a questionnaire about sunlight exposure. Interventions in both groups are given for four weeks. Baseline blood tests, including serum 25(OH)D, 1,25(OH)2D, VDBP, and 24,25(OH)2D are performed at recruitment. After four weeks of interventions, the maternal venous blood is collected to assess serum 25(OH)D, 1,25(OH)2D, VDBP, and 24,25(OH)2D.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Vitamin D Deficiency

7. Study Design

Primary Purpose
Treatment
Study Phase
Phase 2, Phase 3
Interventional Study Model
Parallel Assignment
Masking
None (Open Label)
Allocation
Randomized
Enrollment
52 (Actual)

8. Arms, Groups, and Interventions

Arm Title
50,000 IU
Arm Type
Experimental
Arm Description
Vitamin D3 50,000 IU weekly a standard prenatal multivitamin (fumarate Fe 90 mg; folic acid 0.4 mg; vitamin B6 3 mg; vitamin B12 5 mcg; sulphate cupric 0.35 mg, sulphate cobalt 0.15 mg, sulphate mangan 5 mcg, vitamin C 60 mg, vitamin E 5 mg, and phosphate calcium 60 mg)
Arm Title
5,000 IU
Arm Type
Active Comparator
Arm Description
Vitamin D3 5,000 IU daily a standard prenatal multivitamin (fumarate Fe 90 mg; folic acid 0.4 mg; vitamin B6 3 mg; vitamin B12 5 mcg; sulphate cupric 0.35 mg, sulphate cobalt 0.15 mg, sulphate mangan 5 mcg, vitamin C 60 mg, vitamin E 5 mg, and phosphate calcium 60 mg)
Intervention Type
Drug
Intervention Name(s)
Cholecalciferol
Other Intervention Name(s)
vitamin D
Intervention Description
vitamin D3
Primary Outcome Measure Information:
Title
25(OH)D maternal serum level
Description
quantified by direct competitive Chemilumiscence Immunoassay (CLIA) using LIAISON®.
Time Frame
4 weeks after intervention
Title
1,25(OH)2D maternal serum level
Description
quantified by Liquid Chromatography-tandem Mass Spectrometry (LC-MS/MS) using ImmuTube®.
Time Frame
4 weeks after intervention
Title
VDBP maternal serum level
Description
quantified by Enzyme-Linked Immunosorbent Assay (ELISA) using Quantikine®
Time Frame
4 weeks after intervention
Title
24,25(OH)2D maternal serum level
Description
quantified by Acquity I Class Binary Solvent Manager FTN , Xevo TQXS Tandem Mass Spectrometry (Waters Corporation)
Time Frame
4 weeks after intervention

10. Eligibility

Sex
Female
Accepts Healthy Volunteers
Accepts Healthy Volunteers
Eligibility Criteria
Inclusion Criteria: pregnant women with gestational age of ≤ 14 weeks vitamin D deficient or insufficient (25(OH)D <30 ng/ml] positive fetal heart rate from ultrasound examination. Exclusion Criteria: multiple pregnancy pregnancy with congenital anomaly hyperemesis gravidarum, diarrhea complicated medical history (hypertension, diabetes mellitus, heart, kidney, or liver disease) use of any dietary supplement containing vitamin D prior to enrolment
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Rima Irwinda, MD, PhD
Organizational Affiliation
Departement of Obstetrics and Gynecology, Faculty of Medicine University of Indonesia
Official's Role
Study Chair
Facility Information:
Facility Name
Cipto Mangunkusumo National Center General Hospital
City
Jakarta Pusat
State/Province
DKI Jakarta
ZIP/Postal Code
13730
Country
Indonesia

12. IPD Sharing Statement

Plan to Share IPD
Yes
IPD Sharing Plan Description
The research findings will be disseminated via publication of results, submission of information to public accessible databases, or meetings
IPD Sharing Time Frame
the data will become available in June 2024
IPD Sharing Access Criteria
there is no access criteria

Learn more about this trial

The Effect of Vitamin D3 Therapy on Vitamin D Status in Pregnant Women With Vitamin D Deficient and Insufficient

We'll reach out to this number within 24 hrs